Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc., formerly known as Aurasense Therapeutics, is a pioneering biotechnology company that is redefining the landscape of immunomodulatory and gene silencing drugs. Leveraging its proprietary 3-dimensional Spherical Nucleic Acid (SNA™) architecture, Exicure is unlocking the therapeutic potential of nucleic acids across multiple organs. The company focuses on developing treatments targeting validated pathways for conditions ranging from inflammatory disorders to oncology.
Exicure's innovative SNA constructs are designed to overcome one of the most significant challenges in nucleic acid therapeutics: the efficient and safe delivery of therapeutic agents into cells and tissues. These constructs offer unparalleled transfection efficiency into various cell and tissue types, including skin, without the need for carriers or transfection agents. Additionally, SNA constructs hold promise as potent immunotherapeutic agents for addressing cancer and infectious diseases.
At the forefront of Exicure's pipeline are treatments for neurological disorders and hair loss, targeting ribonucleic acid (RNA) against validated disease targets. The company operates in a single segment focused on the discovery, research, and development of SNA-based treatments.
Recent milestones for Exicure include advancements in its lead programs, successful preclinical results, and strategic partnerships aimed at accelerating the development and commercialization of its groundbreaking therapies. These achievements underscore the company's commitment to transforming the future of medicine through cutting-edge nucleic acid technology.
The latest news and updates about Exicure, Inc. highlight the company's ongoing progress and significant developments in the biotechnology sector, providing valuable insights for investors and stakeholders.
Exicure (Nasdaq: XCUR), an early-stage biotech firm, reported its Q1 2024 financial results. The company has halted all R&D activities, focusing on strategic alternatives. Cash and equivalents dropped to $0.4 million by March 31, 2024, from $0.8 million in December 2023, further dipping to $0.2 million by May 2024. A $0.7 million loan was secured in May 2024. Revenue included a $0.5 million initial payment from a patent license agreement for cavrotolimod. R&D expenses decreased to $0 versus $1.4 million YoY, and G&A expenses fell to $1.3 million from $3.1 million YoY. Net loss improved to $0.8 million from $4.4 million YoY. Management expresses urgent need for additional financing to sustain operations and explore strategic options.
Exicure (Nasdaq: XCUR) reported its full-year 2023 financial results, highlighting a significant reduction in operations and financial strain.
As of December 31, 2023, the company’s cash and cash equivalents stood at $0.8 million, down from $8.6 million in 2022, further dropping to $0.2 million by May 31, 2024. Exicure received a $0.7 million loan from DGP Co., to cover immediate financial needs.
Research and development expenses decreased drastically to $1.4 million from $19.8 million in 2022, following the suspension of clinical, preclinical, and discovery program activities.
General and administrative expenses rose to $12.7 million from $10.9 million. The net loss for the year increased to $16.9 million, significantly higher than the $2.6 million loss in 2022, due to the absence of revenue.
Management disclosed concerns over the company's ability to continue operations without substantial additional financing in the near term.
Exicure has received a delisting determination notice from Nasdaq for not filing its Form 10-K for 2023 and Form 10-Q for Q1 2024 by the extended deadline of May 20, 2024. Trading of Exicure's stock will be suspended on May 30, 2024, unless the company appeals by May 28, 2024. Failure to appeal will result in a Form 25-NSE being filed with the SEC, removing Exicure's securities from Nasdaq. Additionally, Exicure has not held its 2023 Annual Meeting of Stockholders, which is another basis for delisting. Exicure intends to appeal and file the required forms as soon as possible.
Exicure (Nasdaq: XCUR) reported its third-quarter 2023 financial results. The company, which halted all R&D activities in September 2022 to explore strategic alternatives, had cash and equivalents of $0.9 million as of September 30, 2023, down from $8.6 million at the end of 2022, and further decreased to $0.2 million by April 30, 2024.
R&D expenses were $0 for Q3 2023, compared to $4.8 million for the same period in 2022. General and administrative expenses remained steady at $2.4 million. The net loss was $5.3 million, slightly up from $5.2 million in Q3 2022, mainly due to a loss on debt securities.
The company urgently needs additional funding to continue operations, as current cash levels are insufficient.
FAQ
What is the current stock price of Exicure (XCUR)?
What is the market cap of Exicure (XCUR)?
What does Exicure, Inc. specialize in?
What are the key areas of focus for Exicure's treatments?
What makes Exicure's SNA constructs unique?
What are some recent achievements of Exicure, Inc.?
How does Exicure contribute to cancer and infectious disease treatment?
What is the primary technology used by Exicure, Inc.?
What segment does Exicure operate in?
How does Exicure ensure the safe delivery of nucleic acid therapeutics?
What are the target diseases for Exicure's lead programs?
Where can I find the latest news about Exicure, Inc.?
